|
**Overview**: Sphingolipidosis 2 Panel**Introduction**: The Sphingolipidosis 2 Panel is a diagnostic tool designed to screen for sphingolipidosis disorders using whole blood samples. In India, disorders like Gaucher (GBA), Niemann-Pick A/B (SMPD1), Tay-Sachs (HEXA), Niemann-Pick C (NPC1), Krabbe (GALC), and MLD (PSAP) present with hepatosplenomegaly, neurodegeneration, or developmental regression, often misdiagnosed as other metabolic conditions in resource-limited settings. High morbidity from under-testing in rural/low-SES children with unexplained neurological decline or organomegaly, limited genetic testing, delayed substrate reduction or chaperone therapy leading to irreversible damage. Per pediatrics/genetics practices aligned with ICMR and Indian Society for Inborn Errors of Metabolism guidelines, the test employs PCR for 6 key genes over 1-2 days with high accuracy, valuable for differential diagnosis in suspected lysosomal storage disease. This diagnostic falls under genetic disorder screening and targets children with regression, cherry-red spot, or hepatosplenomegaly, addressing accurate detection to guide specific therapy or palliative care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular identification and reducing family burden. Its whole blood-based approach ensures reliable mutation detection.**Other Names**: Sphingo 2 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Expanded LSD panels standard; in India, used in tertiary IEM centers.**Purpose**: The test assesses 6 parameters including GBA (Gaucher) to guide sphingolipidosis screening, detect mutations, inform therapy.**Test Parameters**: 1. GBA (Gaucher), 2. SMPD1 (Niemann-Pick A/B), 3. HEXA (Tay-Sachs), 4. NPC1 (Niemann-Pick C), 5. GALC (Krabbe), 6. PSAP (MLD).**Pretest Condition**: No fasting required; patients should have neurological regression.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on regression, organomegaly, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected LSD including deterioration, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Pathogenic mutation confirms disorder, necessitating specialist input.**Specialist Consultation**: Pediatric metabolic specialists or geneticists should be consulted for management.**Additional Supporting Tests**: Enzyme assays, chitotriosidase for confirmation.**Test Limitations**: Detects common mutations; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, IEM Studies India 2023. |
